- |||||||||| Trial completion, Enrollment change: Optical Polyp Testing for In Vivo Classification (clinicaltrials.gov) - Apr 16, 2019
P=N/A, N=13, Completed,
Trial completion date: Aug 2017 --> Aug 2018 Recruiting --> Completed | N=20 --> 13
- |||||||||| NN1213 / Novo Nordisk
Enrollment change, Trial completion date, Trial termination, Trial primary completion date, Metastases: CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (clinicaltrials.gov) - Apr 2, 2019
P=N/A, N=23, Terminated,
Recruiting --> Completed | N=20 --> 13 N=100000 --> 23 | Trial completion date: Oct 2019 --> Mar 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2019 --> Mar 2019; Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data.
- |||||||||| Trial completion: Retroview (clinicaltrials.gov) - Feb 27, 2019
P=N/A, N=100, Completed,
Enrolling by invitation --> Completed | N=3451 --> 1636 Recruiting --> Completed
- |||||||||| Trial completion, Trial completion date: Behavioral Economic Incentives and Cancer Health Risk Assessment (clinicaltrials.gov) - Feb 20, 2019
P=N/A, N=2000, Completed,
Enrolling by invitation --> Completed | Trial completion date: Dec 2018 --> Nov 2017 Active, not recruiting --> Completed | Trial completion date: Dec 2018 --> Nov 2017
- |||||||||| NN1213 / Novo Nordisk
Trial completion: MOST: Mediterranean Oncology Senior Tests (clinicaltrials.gov) - Jan 15, 2019
P=N/A, N=180, Completed,
Trial primary completion date: Jul 2100 --> Feb 2019 | Recruiting --> Completed | N=902 --> 2059 Active, not recruiting --> Completed
- |||||||||| alisertib (MLN8237) / Puma
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Metastases: Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer (clinicaltrials.gov) - Jan 4, 2019
P1, N=17, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=42 --> 17 | Trial completion date: Dec 2019 --> Oct 2016 | Trial primary completion date: Dec 2018 --> Oct 2016
- |||||||||| Trial completion: Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors (clinicaltrials.gov) - Jan 4, 2019
P=N/A, N=45, Completed,
Active, not recruiting --> Completed | N=42 --> 17 | Trial completion date: Dec 2019 --> Oct 2016 | Trial primary completion date: Dec 2018 --> Oct 2016 Recruiting --> Completed
- |||||||||| veliparib (ABT-888) / AbbVie
Trial termination, Combination therapy, BRCA Biomarker, PARP Biomarker, Metastases: Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jan 3, 2019
P1, N=16, Terminated,
Active, not recruiting --> Completed Active, not recruiting --> Terminated
- |||||||||| Enrollment change, Trial completion date, Trial termination: Molecular Genetic and Pathological Studies of Anal Tumors (clinicaltrials.gov) - Dec 10, 2018
P=N/A, N=7, Terminated,
Active, not recruiting --> Terminated N=300 --> 7 | Trial completion date: Dec 2013 --> Dec 2017 | Recruiting --> Terminated
- |||||||||| Enrollment change, Trial completion date, HEOR: The Inland Northwest Colon Cancer Survivor's Study (clinicaltrials.gov) - Dec 6, 2018
P=N/A, N=25, Completed,
N=300 --> 7 | Trial completion date: Dec 2013 --> Dec 2017 | Recruiting --> Terminated N=60 --> 25 | Trial completion date: Jun 2015 --> Dec 2018
- |||||||||| NN1213 / Novo Nordisk
Trial completion, Trial completion date: Evaluating Strategies to Present Colon Cancer Screening Information (clinicaltrials.gov) - Nov 15, 2018
P=N/A, N=486, Completed,
Recruiting --> Active, not recruiting | Trial completion date: Dec 2017 --> Dec 2022 | Trial primary completion date: Dec 2017 --> Dec 2022 Active, not recruiting --> Completed | Trial completion date: May 2017 --> Jan 2017
- |||||||||| Trial completion date, Trial initiation date, Trial primary completion date: PROMENADE: Proactive Management of Endoperitoneal Spread in Colonic Cancer (clinicaltrials.gov) - Nov 9, 2018
P3, N=140, Not yet recruiting,
Active, not recruiting --> Completed | Trial completion date: May 2017 --> Jan 2017 Trial completion date: Mar 2025 --> Sep 2025 | Initiation date: Sep 2018 --> Mar 2019 | Trial primary completion date: Mar 2023 --> Sep 2023
- |||||||||| Enrollment change, Trial completion date, Trial withdrawal, Trial primary completion date: Novel Listeria Vectors Secreting Gut Flora-Altering Agents to Prevent Colon Cancer and Treat Colitis (clinicaltrials.gov) - Sep 17, 2018
P=N/A, N=0, Withdrawn,
Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: May 2018 --> May 2019 N=100 --> 0 | Trial completion date: Dec 2023 --> Sep 2018 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2023 --> Sep 2018
- |||||||||| Erbitux (cetuximab) / Eli Lilly
Enrollment change, Trial termination, Surgery, Metastases: COMBATAC: Combined Anticancer Treatment of Advanced Colon Cancer (clinicaltrials.gov) - Sep 5, 2018
P2, N=26, Terminated,
N=100 --> 0 | Trial completion date: Dec 2023 --> Sep 2018 | Recruiting --> Withdrawn | Trial primary completion date: Dec 2023 --> Sep 2018 N=60 --> 26 | Active, not recruiting --> Terminated; Slow recruitment.
- |||||||||| NN1213 / Novo Nordisk
Enrollment closed, Trial completion date, Trial primary completion date, Metastases: CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing and Treated by Physician Choice (clinicaltrials.gov) - Aug 3, 2018
P=N/A, N=100000, Active, not recruiting,
Trial completion date: Jul 2018 --> Dec 2018 Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Oct 2019 | Trial primary completion date: Oct 2021 --> Oct 2019
- |||||||||| Trial completion date: Colorectal Cancer Screening in a Community Health Setting (clinicaltrials.gov) - Aug 2, 2018
P=N/A, N=320, Enrolling by invitation,
Recruiting --> Active, not recruiting | Trial completion date: Oct 2024 --> Oct 2019 | Trial primary completion date: Oct 2021 --> Oct 2019 Trial completion date: Jun 2018 --> Sep 2018
- |||||||||| NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: Study on Cannabinoid Receptor Expression in Gastrointestinal Diseases (clinicaltrials.gov) - Jul 30, 2018
P=N/A, N=31, Completed,
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Jul 2018 | Trial primary completion date: Apr 2020 --> Jul 2018
- |||||||||| NN1213 / Novo Nordisk
Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer (clinicaltrials.gov) - Jul 20, 2018
P=N/A, N=18, Completed,
Active, not recruiting --> Completed | Trial completion date: Apr 2020 --> Jul 2018 | Trial primary completion date: Apr 2020 --> Jul 2018 Recruiting --> Completed | N=72 --> 18 | Trial completion date: Dec 2018 --> Jul 2018 | Trial primary completion date: Dec 2018 --> Jun 2018
- |||||||||| Trial completion date, Trial primary completion date: Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors (clinicaltrials.gov) - Jun 26, 2018
P=N/A, N=45, Recruiting,
Not yet recruiting --> Recruiting Trial completion date: Apr 2018 --> Nov 2018 | Trial primary completion date: Oct 2017 --> Nov 2018
- |||||||||| NGC-capecitabine (PCS6422) / Processa Pharma
Enrollment change, Trial termination: Eniluracil Hand Foot Syndrome (clinicaltrials.gov) - Jun 2, 2018
P1, N=3, Terminated,
Trial completion date: Apr 2018 --> Nov 2018 | Trial primary completion date: Oct 2017 --> Nov 2018 N=35 --> 3 | Completed --> Terminated
- |||||||||| Enrollment closed, Phase classification, Trial completion date, Trial primary completion date: Ultrasound Therapy and Therapeutic Exercise for Chemotherapy Induced Peripheral Neuropathy (CIPN) (clinicaltrials.gov) - Apr 10, 2018
P=N/A, N=31, Active, not recruiting,
Trial primary completion date: Mar 2018 --> Dec 2018 Recruiting --> Active, not recruiting | Phase classification: P1 --> PN/A | Trial completion date: Dec 2017 --> Jul 2018 | Trial primary completion date: Apr 2017 --> Sep 2017
- |||||||||| Trial completion, Phase classification, Trial completion date, Trial primary completion date: Study Comparing Two Strategies of Exercise in Breast and Colon Cancer Survivors and Their Impact on Fatigue (clinicaltrials.gov) - Apr 6, 2018
P=N/A, N=32, Completed,
Recruiting --> Active, not recruiting | Phase classification: P1 --> PN/A | Trial completion date: Dec 2017 --> Jul 2018 | Trial primary completion date: Apr 2017 --> Sep 2017 Recruiting --> Completed | Phase classification: P2 --> PN/A | Trial completion date: Apr 2017 --> Sep 2017 | Trial primary completion date: Nov 2016 --> Sep 2017
- |||||||||| Trial completion, Trial completion date, Trial primary completion date: Retrospective Study on Epidemiology of Colorectal Lesions (clinicaltrials.gov) - Mar 7, 2018
P=N/A, N=2658, Completed,
Trial completion date: Jan 2018 --> Jun 2018 Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Mar 2018 | Trial primary completion date: Jun 2017 --> Feb 2018
- |||||||||| Trial completion date, Trial primary completion date: Low Glycemic Load Diet in Patients With Stage I-III Colon Cancer (clinicaltrials.gov) - Feb 27, 2018
P=N/A, N=72, Recruiting,
Active, not recruiting --> Completed | Trial completion date: Jul 2017 --> Mar 2018 | Trial primary completion date: Jun 2017 --> Feb 2018 Trial primary completion date: Sep 2017 --> Dec 2018 | Trial completion date: Sep 2017 --> Dec 2018
- |||||||||| Enrollment change, Trial completion date, Trial initiation date, Trial termination, Trial primary completion date, Metastases: Irinotecan-Eluting Beads in Treating Patients With Refractory Metastatic Colon or Rectal Cancer That Has Spread to the Liver (clinicaltrials.gov) - Feb 26, 2018
P1, N=2, Terminated,
Trial primary completion date: Sep 2017 --> Dec 2018 | Trial completion date: Sep 2017 --> Dec 2018 N=30 --> 2 | Recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Apr 2017 | Trial completion date: Apr 2019 --> Aug 2017 | Initiation date: Jan 2016 --> Jan 2016; IRB study closure by investigator due to low enrollment
- |||||||||| floxuridine / Generic mfg., gemcitabine / Generic mfg.
Trial completion, Enrollment change, Trial completion date, Trial primary completion date, Surgery, Metastases: Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery (clinicaltrials.gov) - Feb 20, 2018
P1/2, N=16, Completed,
N=30 --> 2 | Recruiting --> Terminated | Trial primary completion date: Apr 2018 --> Apr 2017 | Trial completion date: Apr 2019 --> Aug 2017 | Initiation date: Jan 2016 --> Jan 2016; IRB study closure by investigator due to low enrollment Active, not recruiting --> Completed | N=28 --> 16 | Trial primary completion date: Jul 2018 --> Feb 2018 | Trial completion date: Jul 2018 --> Feb 2018
|
